GMED — Globus Medical Income Statement
0.000.00%
Last trade - 00:00
- $9.44bn
- $9.38bn
- $1.57bn
- 84
- 21
- 97
- 75
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 785 | 789 | 958 | 1,023 | 1,568 |
Cost of Revenue | |||||
Gross Profit | 605 | 572 | 719 | 759 | 1,020 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 613 | 678 | 786 | 795 | 1,435 |
Operating Profit | 172 | 111 | 172 | 228 | 133 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 190 | 126 | 180 | 243 | 165 |
Provision for Income Taxes | |||||
Net Income After Taxes | 155 | 102 | 149 | 190 | 123 |
Net Income Before Extraordinary Items | |||||
Net Income | 155 | 102 | 149 | 190 | 123 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 155 | 102 | 149 | 190 | 123 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.56 | 1.05 | 1.62 | 1.92 | 1.52 |